Characteristics and Outcomes of Acute Myeloid Leukemia (AML) Patients Treated With Oral-Azacitidine Maintenance Therapy in France (RELION)
RELION Study: Characteristics and Outcomes of the Patient Population With Acute Myeloid Leukemia in Remission, Treated With Oral Azacitidine Maintenance in France
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75002
- Kappa Santé
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Participants who initiated oral azacitidine maintenance therapy during early access program (EAP) in France (January 29, 2021 to July 13, 2022) or during the 6 months post-EAP (from July 14, 2022, to January 2014, 2023) inside the marketing authorization label "adult patients with acute myeloid leukaemia (AML) who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (HSCT)."
- Participants with histologically confirmed diagnosis of de novo AML, or therapy-related AML, or secondary AML
- Participants who received frontline treatment after diagnosis of AML and achieved complete remission (CR), CR with incomplete blood count recovery (Cri), or CR with partial hematology recovery (CRh) after one or subsequent lines of therapy in case of relapse
- Participant is at least 18 years of age at the time of initial diagnosis of AML
- Participants alive or deceased at the time of data collection
Physician has access to the complete medical record for the patient, including any transferred records from other facilities (if applicable); patient's medical record must at least include the following:
- Date of diagnosis of AML
- Frontline therapy(ies) received, and treatment start dates
- Date(s) of first documented evidence of response
- Oral azacitidine start and (if applicable) stop date
- Documentation (yes/no) of relapse on oral azacitidine, where applicable
- Participants who do not object to the data collection
Exclusion Criteria:
- Participants who initiated maintenance with oral azacitidine after January 14, 2023
- Participant who initiated maintenance with oral azacitidine before January 14, 2023, outside of the marketing authorization label
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Participants that received maintenance treatment of oral azacitidine
|
As per product label, prescribed by treating physician
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Participant real-world relapse-free survival (rw-RFS)
Time Frame: Up to date of documented relapse or death assessed up to 41 months
|
Up to date of documented relapse or death assessed up to 41 months
|
|
Participant overall survival (OS)
Time Frame: Up to date of documented death assessed up to 41 months
|
Up to date of documented death assessed up to 41 months
|
|
Participant relapsed-free survival (RFS)
Time Frame: From date of achieved complete remission up to 41 months
|
From date of achieved complete remission up to 41 months
|
|
Participant overall survival (OS) from the time of complete remission achievement
Time Frame: From date of achieved complete remission up to 41 months
|
From date of achieved complete remission up to 41 months
|
|
Participant relapse rate
Time Frame: 6 and 12 months
|
6 and 12 months
|
|
Time to treatment discontinuation (TTD)
Time Frame: Up to 41 months
|
Up to 41 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Participant treatment history
Time Frame: Baseline
|
Baseline
|
|
|
Participant baseline demographics
Time Frame: Baseline
|
Baseline
|
|
|
Type of acute myeloid (AML)
Time Frame: Baseline
|
AML types include: de novo, or secondary AML (therapy-related AML, or secondary to a myeloid disorder)
|
Baseline
|
|
Participant cytogenetic abnomalities
Time Frame: Baseline
|
Baseline
|
|
|
Participant gene mutation status
Time Frame: Baseline
|
Baseline
|
|
|
Participant cytogenetic and mutational risk category
Time Frame: Baseline
|
Baseline
|
|
|
Participant acute myeloid (AML) classification as per World Health Organization
Time Frame: Baseline
|
Baseline
|
|
|
Participant bone marrow blast percentage
Time Frame: Baseline
|
Baseline
|
|
|
Participant hemoglobin levels
Time Frame: Baseline
|
Baseline
|
|
|
Participant blood test results
Time Frame: Baseline
|
Baseline
|
|
|
Participant Eastern Cooperative Oncology Group or Karnofsky score
Time Frame: Baseline
|
Baseline
|
|
|
Participant diagnosis history of other hematological disorders
Time Frame: Baseline
|
Baseline
|
|
|
Minimal residual disease status (MRD)
Time Frame: Baseline
|
Baseline
|
|
|
Reason for stem cell transplant ineligibility post initial frontline treatment
Time Frame: Baseline
|
Baseline
|
|
|
Participant response type at the initiation of maintenance therapy
Time Frame: Up to 41 months
|
Response types include: complete remission (CR), incomplete blood count recovery (Cri) or CR with partial hematology recovery (CRh)
|
Up to 41 months
|
|
First versus subsequent remission at the time of initiation of treatment with oral azacitidine
Time Frame: Baseline
|
Baseline
|
|
|
Criteria to define complete remission (CR), incomplete blood count recovery (Cri), and CR with partial hematology recovery (CRh) at time of initiation of oral azacitidine
Time Frame: Baseline
|
Baseline
|
|
|
Oral azacitidine treatment regimen
Time Frame: Up to 41 months
|
Up to 41 months
|
|
|
Concomitant support treatment received with oral azacitidine
Time Frame: Up to 41 months
|
Up to 41 months
|
|
|
Duration of oral azacitidine treatment
Time Frame: Up to 41 months
|
Up to 41 months
|
|
|
Reason for oral azacitidine treatment discontinuation
Time Frame: Up to 41 months
|
Up to 41 months
|
|
|
Treatments/procedures following oral azacitidine cessation
Time Frame: Up to 41 months
|
Up to 41 months
|
|
|
Participant adverse events (AEs)
Time Frame: Up to 41 months
|
Up to 41 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms
- Neoplasms by Histologic Type
- Hematologic Diseases
- Leukemia, Myeloid
- Leukemia
- Hemic and Lymphatic Diseases
- Leukemia, Myeloid, Acute
- Organic Chemicals
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Nucleic Acids, Nucleotides, and Nucleosides
- Cytidine
- Pyrimidine Nucleosides
- Pyrimidines
- Aza Compounds
- Nucleosides
- Ribonucleosides
- Azacitidine
Other Study ID Numbers
Other Study ID Numbers
- CA055-1047
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.